Literature DB >> 3141407

The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets.

M E Nesheim1, D D Pittman, J H Wang, D Slonosky, A R Giles, R J Kaufman.   

Abstract

Recombinant-derived human Factor VIII was labeled intrinsically with [35S]methionine, and its binding to washed human platelets was studied. Binding measurements were performed by incubating Factor VIII and platelets for 15 min at room temperature in Tyrode's solution supplemented with Ca2+ (5.0 mM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (5.0 mM), 0.50% bovine serum albumin, and the Factor Xa and thrombin inhibitors 5-dimethylaminonaphthalene-1-sulfonylglutamylglycinylarginyl chloromethyl ketone and 5-dimethylaminonaphthalene-1-sulfonyl-arginine-N-(3-ethyl-1, 5-pentanediyl)amide. Separation of free from bound Factor VIII was accomplished by centrifugation through oil, and nonspecific binding was determined with excess unlabeled Factor VIII. Binding was saturable, reversible, and stimulated 20-fold after platelet activation with thrombin. Furthermore, binding was specific in that bound labeled Factor VIII could be displaced by excess unlabeled Factor VIII, but not by Factor V. Scatchard analysis indicated a single class of binding sites with Kd = 2.9 nM and 450 sites/activated platelet. The time course of displacement indicated a t1/2 of bound Factor VIII of approximately 5 min. When platelets were incubated in Ca2+, both the heavy and light chains of Factor VIII were bound, whereas exposure to EDTA resulted in the binding of the light chain only. These results demonstrate the specific reversible binding of Factor VIII to human platelets, likely mediated through the light chain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141407

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  PAR-1-stimulated factor IXa binding to a small platelet subpopulation requires a pronounced and sustained increase of cytoplasmic calcium.

Authors:  Fredda S London; Mariola Marcinkiewicz; Peter N Walsh
Journal:  Biochemistry       Date:  2006-06-13       Impact factor: 3.162

Review 2.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

3.  Platelet receptor-mediated factor X activation by factor IXa. High-affinity factor IXa receptors induced by factor VIII are deficient on platelets in Scott syndrome.

Authors:  S S Ahmad; R Rawala-Sheikh; B Ashby; P N Walsh
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

4.  Grow with the flow: a spatial-temporal model of platelet deposition and blood coagulation under flow.

Authors:  Karin Leiderman; Aaron L Fogelson
Journal:  Math Med Biol       Date:  2010-05-03       Impact factor: 1.854

5.  A Mathematical Model of Venous Thrombosis Initiation.

Authors:  Priscilla Elizondo; Aaron L Fogelson
Journal:  Biophys J       Date:  2016-12-20       Impact factor: 4.033

6.  A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain.

Authors:  J D Johnson; J C Edman; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

7.  An ordered sequential mechanism for Factor IX and Factor IXa binding to platelet receptors in the assembly of the Factor X-activating complex.

Authors:  Xia Yang; Peter N Walsh
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

Review 8.  Thrombin generation, fibrin clot formation and hemostasis.

Authors:  Alisa S Wolberg; Robert A Campbell
Journal:  Transfus Apher Sci       Date:  2008-02-20       Impact factor: 1.764

9.  A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2.

Authors:  T G Diacovo; A R deFougerolles; D F Bainton; T A Springer
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

10.  Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.

Authors:  T L Ortel; M A Quinn-Allen; L A Charles; D Devore-Carter; W H Kane
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.